Benefits
Oral use studied only in high-risk dermatology patients (not a general skin benefit)
In the ONTRAC trial, patients who had already had at least two non-melanoma skin cancers took oral niacinamide 500 mg twice daily; new skin-cancer counts were 23% lower than placebo over 12 months (P=0.02), and the benefit stopped once the pills stopped. This is a finding in high-risk skin-cancer patients under dermatology care, not a general skin-appearance benefit for a healthy buyer, and it did not replicate: a 2023 trial in organ-transplant recipients (ONTRANS) found no reduction in skin cancers (rate ratio 1.0).
Hyperpigmentation reduction (topical)
This is topical-cream evidence and does not describe the oral DermaNiA capsule. Applied to the skin at 2-5%, niacinamide reduced facial hyperpigmented spots versus a vehicle control in dose-dependent fashion by inhibiting melanosome transfer. No oral trial has shown that a swallowed dose reduces hyperpigmentation.
Skin barrier function improvement (topical)
This is topical-application evidence and does not describe the oral capsule. Applied to the skin, niacinamide raises ceramide, free fatty acid and cholesterol synthesis in keratinocytes, and topical RCTs report reduced transepidermal water loss and better hydration. No oral trial has shown a swallowed dose improves the skin barrier.
Anti-aging skin improvements (topical)
This is topical-cream evidence and does not describe the oral capsule. Applied at 5% versus a vehicle control, niacinamide improved fine lines, hyperpigmented spots, texture, red blotchiness and sallowness. No oral trial has tested whether a swallowed dose changes facial aging.
Acne (topical evidence)
The strong result here is topical: applied at 4%, niacinamide reduced inflammatory acne comparably to topical clindamycin. Oral niacinamide has only been tested for acne inside multi-ingredient products (for example combined with zinc and copper), so any benefit cannot be attributed to niacinamide alone, and neither result describes DermaNiA taken on its own.
NAD+ precursor pathway
Niacinamide is converted to NAD+ (nicotinamide adenine dinucleotide), the key cellular coenzyme for redox reactions, DNA repair (via PARP enzymes), and energy metabolism. NAD+ levels decline with age; skin NAD+ specifically decreases with UV exposure and oxidative stress. Restoring NAD+ via niacinamide supports broader cellular maintenance.
Mechanism of action
NAD+ pool restoration
Niacinamide is the most direct precursor to NAD+ via the salvage pathway, bypassing the slower de novo synthesis from tryptophan. Increased NAD+ supports mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin activity. Distinct from precursors like NR (nicotinamide riboside) which feed the same pathway via a different entry point.
Melanosome transfer inhibition (topical)
Niacinamide inhibits the transfer of mature melanosomes from melanocytes to surrounding keratinocytes — the rate-limiting step in skin pigmentation. Distinct from tyrosinase inhibition (hydroquinone, kojic acid) which prevents melanin synthesis. Both mechanisms can reduce hyperpigmentation, but niacinamide's approach is gentler and has lower irritation profile.
Anti-inflammatory and immunomodulatory effects
Niacinamide inhibits poly(ADP-ribose) polymerase (PARP) hyperactivation in UV-damaged cells, reducing inflammatory cytokine release. Also suppresses neutrophil chemotaxis and Th17 inflammatory responses — relevant to acne, rosacea, and inflammatory dermatoses.
Photoimmunoprotection (proposed mechanism for the skin-cancer trial)
Oral niacinamide preserves cellular ATP after UV exposure, reduces UV-induced immunosuppression, and enhances DNA repair via PARP energy preservation. These mechanisms collectively reduce UV-mutagenesis and explain the NMSC chemoprevention effect.
Clinical trials
Phase 3 randomized double-blind placebo-controlled trial in 386 patients with ≥2 NMSCs in the previous 5 years. Intervention: niacinamide 500 mg twice daily or placebo for 12 months.
386 patients with ≥2 NMSCs
Phase 3 randomized double-blind placebo-controlled trial in 386 patients with ≥2 NMSCs in the previous 5 years. Intervention: niacinamide 500 mg twice daily or placebo for 12 months. Outcome: 23% reduction in new NMSC incidence (P=0.02) — primary endpoint. Only the composite skin-cancer count reached clear significance: basal cell carcinomas fell 20% (P=0.12, not significant) and squamous cell carcinomas 30% (P=0.05, borderline). Actinic keratoses were significantly reduced, 20% lower at 9 months and 13% lower at the 12-month endpoint (P=0.001). Effect disappeared within 6 months of discontinuation. Published in NEJM 2015; incorporated into dermatology clinical practice for high-NMSC-risk patients.
A vehicle-controlled split-face study in Japanese women testing a topical niacinamide product (2% and 5%) on facial hyperpigmentation; topical application, not the oral capsule.
Japanese women (topical split-face study)
In this topical split-face study, a niacinamide cream at 2% and 5% reduced facial hyperpigmented spots in a dose-dependent way, and the effect reversed within about 8 weeks of stopping. This is evidence for niacinamide applied to the skin, not for a swallowed capsule. Published in the British Journal of Dermatology (2002).